Ivermectin + cancer: early human trial results from a conference report (update скачать в хорошем качестве

Ivermectin + cancer: early human trial results from a conference report (update

Could a common anti-parasitic drug help fight triple negative breast cancer? We dive into the latest Phase I/II study combining ivermectin with immunotherapy for patients with heavily pretreated TNBC. Structured Overview: • Background: TNBC is tough to treat; some tumors are “cold” and resistant to immunotherapy. Ivermectin may boost immune response, while balstilimab targets PD-1. • Study Design: Phase I/II, balstilimab 450 mg IV Day 1 + ivermectin orally (days 1–3, 8–10, 15–17 per 21-day cycle), dose escalation across 3 levels (30–60 mg). • Patients: 9 enrolled, median age 52, heavily pretreated; 66% prior immunotherapy; 66% PD-L1 positive. • Safety: Mostly mild side effects; 1 serious anemia; combo appears well tolerated. • Efficacy: Partial response in 1 patient, stable disease in 1; 4-month clinical benefit rate 37.5%. • Dose Escalation: Decision based on dose-limiting toxicities; rules explained for Phase I trials. • Conclusion: Feasible, safe, early signals of benefit; more data needed. ⏱️ Timestamps: 00:00 – Intro and video title 00:40 – Abstract title page 01:42 – Immune Checkpoint Inhibitors boost by mRNA vaxx 03:41 – Turbo cancers videos 06:25 – Parasites + cancer 06:40 – Vaxx vs unvaxx Tregs hypothesis 📍 Filming Location: Capilano Suspension Bridge Park, BC 📄 Described content:  https://ascopubs.org/doi/10.1200/JCO.... 🌐 Stayin touch: Patreon:   / merogenomics   Twitter:   / merogenomics   Facebook:   / merogenomics   Instagram:   / merogenomics   Original Newsletter sign up: https://share.ebforms.com/53718243485... Alternate Newsletter sign up: http://eepurl.com/hesNGf #TripleNegativeBreastCancer #TNBC #CancerResearch #Immunotherapy #Ivermectin #Balstilimab #ClinicalTrials #PhaseI #CancerScience #Oncology #CancerTreatment #MedicalResearch #BreastCancerAwareness #NewTherapies #ScienceExplained